CAR-T Cancer Drugs Get Nod of Approval from ICER
![](https://allianceforpatientaccess.org/wp-content/uploads/2023/11/AdobeStock_118485007-1024x683.jpeg)
Innovative but expensive CAR-T therapies for cancer are worth their price, announced the Institute for Clinical and Economic Review recently. The organization is the self-appointed arbiter of drug costs. But its decision was hardly news for those in the cancer community.